Abstract 292P
Background
Shared decision making (SDM) is a dynamic clinical process where physicians and patients mutually and actively share information and collaborate to discuss available evidence during treatment decisions, and where patients are supported to consider options in order to achieve informed preferences. It has become a hallmark of patient-centered care and communication which highlights physician-patient relationship as the core in improving health outcomes, and refers to the type of care that is responsive to the individual needs and preferences of the patient, ensuring that clinical decisions are aligned with his or her values. In cancer care, preference-sensitive decisions range from screening decisions, to treatment decisions, and to end-of-life care. There is little experience with SDM in the Philippines and its integration into the practice of Oncology. The objective of this study was to explore patient perception and evaluate the extent to which a shared decision-making process is implemented in clinical encounters at the Cancer Institute adult outpatient clinics of the Philippine General Hospital.
Methods
The SDM Q-9 Filipino version was administered to 267 patients who were consulting at the adult outpatient clinics of the Cancer Institute over one month.
Results
More than 90% of the patients surveyed agreed that shared decision-making process were being practiced at the Cancer Institute adult outpatient clinics. Of these, almost half of the respondents answered “somewhat agreed” in all items, except for the domain which sought if the physician helped the patient to understand information which showed stronger trend towards agreement. Notably, the domains involving identification of preferences and shared decision showed weaker trend towards agreement, with 5% and 7% of patients surveyed disagreeing that these steps were being observed in practice, respectively. This indicated that among the nine items of the SDM Q-9, these areas required the most strengthening.
Conclusions
In this study, the investigators observed that cancer patients agreed that shared decision making was being practiced during their clinical encounters with their respective physicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
223P - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)
Presenter: Karim Fizazi
Session: e-Poster Display Session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session